ABOVE: IMMU Stock Chart for the Last 5 days.
May 27, 2008: Immunomedics, Inc. (Nasdaq: IMMU) announced that it will present data on four clinical studies involving drugs that it has in development at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Companies usually do not present negative studies at scientific meetings. Negative studies are clinical studies or investigations that fail to show any benefit of the drug in question as opposed to the standard treatment. This finding in general implies that the drug will not prove to be lucrative to the company.
Therefore, when a company plans to present the results of a new drug that is in clinical trials it implies that the new agent is working as expected and may increase the profitability of the company.
Please Note: IMMU’s stock has increased in price from 2.3 to 2.65 in the last two trading days, an increase of 15%.
The following studies/new agents will be presented by IMMU at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO):
Anti-CD20-veltuzumab in the treatment of lymphomas (solid blood cancer) and how the treatment success is different from rituximab (a rival, older drug)
131-iodine-labetuzumab (phase II study) as a therapy for colorectal liver metastases (colon cancer that has spread to the liver) as compared to the results of the more traditional treatment i.e. single dose RadioImmunotherapy (RAIT)
The ability to combat diffuse large B-cell lymphoma (a solid blood cancer) with Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP)
DOTA-conjugated, anti-CD22 IgG, epratuzumab (a novel agent) and Fractionated radioimmunotherapy as therapy for NHL (Non Hodgkin’s Lymphoma, a solid blood cancer). The results of the new agent will be compared to those of high cumulative doses of 90Y, a more traditional therapy for NHL.
It would be unusual for all of these agents to not show promise. Why would a company present four failed experimental treatments at a major medical conference? IMMU should be observed for an increase in stock price and/or an increase in revenues in the future.
